Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MedTech

European court strikes down hearing aid sensor patent

30 July 2026 A dispute over optical sensor technology in miniature hearing devices ended with the EPO revoking a patent, finding the invention obvious despite ruling it was new over the closest prior art.

Regulation & Industry

Where Big Pharma is betting big in the M&A boom

29 July 2026 Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?

Careers

Fish & Richardson adds AI and medical device specialist

29 July 2026 The engineer-turned-lawyer joins as a principal, bringing 15 years of experience advising on patent strategy across AI, software, and medical devices.

More features

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

Fish & Richardson adds AI and medical device specialist

Boston Scientific overturns $42m patent verdict on appeal

Buying the brains: Why is Big Pharma shopping for innovation?

FisherBroyles and Hong Kong affiliate draft in senior partners

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

AbbVie, Allergan takes on Swiss aesthetics rival over syringe design

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features